396 related articles for article (PubMed ID: 26834066)
1. Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer.
Brambilla E; Le Teuff G; Marguet S; Lantuejoul S; Dunant A; Graziano S; Pirker R; Douillard JY; Le Chevalier T; Filipits M; Rosell R; Kratzke R; Popper H; Soria JC; Shepherd FA; Seymour L; Tsao MS
J Clin Oncol; 2016 Apr; 34(11):1223-30. PubMed ID: 26834066
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis.
Ma X; Le Teuff G; Lacas B; Tsao MS; Graziano S; Pignon JP; Douillard JY; Le Chevalier T; Seymour L; Filipits M; Pirker R; Jänne PA; Shepherd FA; Brambilla E; Soria JC; Hainaut P;
J Thorac Oncol; 2016 Jun; 11(6):850-61. PubMed ID: 26899019
[TBL] [Abstract][Full Text] [Related]
3. Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial.
Zhong WZ; Wang Q; Mao WM; Xu ST; Wu L; Wei YC; Liu YY; Chen C; Cheng Y; Yin R; Yang F; Ren SX; Li XF; Li J; Huang C; Liu ZD; Xu S; Chen KN; Xu SD; Liu LX; Yu P; Wang BH; Ma HT; Yang JJ; Yan HH; Yang XN; Liu SY; Zhou Q; Wu YL
J Clin Oncol; 2021 Mar; 39(7):713-722. PubMed ID: 33332190
[TBL] [Abstract][Full Text] [Related]
4. Benefit of adjuvant chemotherapy for resected pathologic N1 non-small cell lung cancer is unrecognized: A subgroup analysis of the JBR10 trial.
Toubat O; Ding L; Ding K; Wightman SC; Atay SM; Harano T; Kim AW; David EA
Semin Thorac Cardiovasc Surg; 2024 Summer; 36(2):261-270. PubMed ID: 36272526
[TBL] [Abstract][Full Text] [Related]
5. A prognostic model for platinum-doublet as second-line chemotherapy in advanced non-small-cell lung cancer patients.
Mo H; Hao X; Liu Y; Wang L; Hu X; Xu J; Yang S; Xing P; Shi Y; Jia B; Wang Y; Li J; Wang H; Wang Z; Sun Y; Shi Y
Cancer Med; 2016 Jun; 5(6):1116-24. PubMed ID: 26993156
[TBL] [Abstract][Full Text] [Related]
6. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
Pignon JP; Tribodet H; Scagliotti GV; Douillard JY; Shepherd FA; Stephens RJ; Dunant A; Torri V; Rosell R; Seymour L; Spiro SG; Rolland E; Fossati R; Aubert D; Ding K; Waller D; Le Chevalier T;
J Clin Oncol; 2008 Jul; 26(21):3552-9. PubMed ID: 18506026
[TBL] [Abstract][Full Text] [Related]
7. Use and impact of adjuvant chemotherapy in patients with resected non-small cell lung cancer.
Williams CD; Gajra A; Ganti AK; Kelley MJ
Cancer; 2014 Jul; 120(13):1939-47. PubMed ID: 24668613
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors after complete resection of pN2 non-small cell lung cancer.
Sonobe M; Date H; Wada H; Okubo K; Hamakawa H; Teramukai S; Matsumura A; Nakagawa T; Sumitomo S; Miyamoto Y; Okumura N; Takeo S; Kawakami K; Aoki M; Kosaka S;
J Thorac Cardiovasc Surg; 2013 Oct; 146(4):788-95. PubMed ID: 23810113
[TBL] [Abstract][Full Text] [Related]
9. High expression of the transcriptional co-activator p300 predicts poor survival in resectable non-small cell lung cancers.
Hou X; Li Y; Luo RZ; Fu JH; He JH; Zhang LJ; Yang HX
Eur J Surg Oncol; 2012 Jun; 38(6):523-30. PubMed ID: 22440742
[TBL] [Abstract][Full Text] [Related]
10. Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With
Tada H; Mitsudomi T; Misumi T; Sugio K; Tsuboi M; Okamoto I; Iwamoto Y; Sakakura N; Sugawara S; Atagi S; Takahashi T; Hayashi H; Okada M; Inokawa H; Yoshioka H; Takahashi K; Higashiyama M; Yoshino I; Nakagawa K;
J Clin Oncol; 2022 Jan; 40(3):231-241. PubMed ID: 34726958
[TBL] [Abstract][Full Text] [Related]
11. Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection.
Tsao MS; Marguet S; Le Teuff G; Lantuejoul S; Shepherd FA; Seymour L; Kratzke R; Graziano SL; Popper HH; Rosell R; Douillard JY; Le-Chevalier T; Pignon JP; Soria JC; Brambilla EM
J Clin Oncol; 2015 Oct; 33(30):3439-46. PubMed ID: 25918286
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy.
Wu X; Ye Y; Rosell R; Amos CI; Stewart DJ; Hildebrandt MA; Roth JA; Minna JD; Gu J; Lin J; Buch SC; Nukui T; Ramirez Serrano JL; Taron M; Cassidy A; Lu C; Chang JY; Lippman SM; Hong WK; Spitz MR; Romkes M; Yang P
J Natl Cancer Inst; 2011 May; 103(10):817-25. PubMed ID: 21483023
[TBL] [Abstract][Full Text] [Related]
13. Should patients with stage IB non-small cell lung cancer receive adjuvant chemotherapy? A comparison of survival between the 8th and 7th editions of the AJCC TNM staging system for stage IB patients.
Wang J; Wu N; Lv C; Yan S; Yang Y
J Cancer Res Clin Oncol; 2019 Feb; 145(2):463-469. PubMed ID: 30474757
[TBL] [Abstract][Full Text] [Related]
14. Post-operative treatment with cisplatin and vinorelbine in Chinese patients with non-small cell lung cancer: a clinical prospective analysis of 451 patients.
Wang J; Liu F; Huang DX; Jiang B
Asian Pac J Cancer Prev; 2012; 13(9):4505-10. PubMed ID: 23167369
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the Lung Adjuvant Cisplatin Evaluation.
Douillard JY; Tribodet H; Aubert D; Shepherd FA; Rosell R; Ding K; Veillard AS; Seymour L; Le Chevalier T; Spiro S; Stephens R; Pignon JP;
J Thorac Oncol; 2010 Feb; 5(2):220-8. PubMed ID: 20027124
[TBL] [Abstract][Full Text] [Related]
16. Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data.
Rossi A; Chiodini P; Sun JM; O'Brien ME; von Plessen C; Barata F; Park K; Popat S; Bergman B; Parente B; Gallo C; Gridelli C; Perrone F; Di Maio M
Lancet Oncol; 2014 Oct; 15(11):1254-62. PubMed ID: 25232001
[TBL] [Abstract][Full Text] [Related]
17. Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials.
Reiman T; Lai R; Veillard AS; Paris E; Soria JC; Rosell R; Taron M; Graziano S; Kratzke R; Seymour L; Shepherd FA; Pignon JP; Sève P
Ann Oncol; 2012 Jan; 23(1):86-93. PubMed ID: 21471564
[TBL] [Abstract][Full Text] [Related]
18. Preoperative lymphocyte count is a favorable prognostic factor of disease-free survival in non-small-cell lung cancer.
Zhang J; Huang SH; Li H; Li Y; Chen XL; Zhang WQ; Chen HG; Gu LJ
Med Oncol; 2013 Mar; 30(1):352. PubMed ID: 23275140
[TBL] [Abstract][Full Text] [Related]
19. Neo-adjuvant chemo/immunotherapy in the treatment of stage III (N2) non-small cell lung cancer: a phase I/II pilot study.
Ratto GB; Costa R; Maineri P; Alloisio A; Piras MT; D'Agostino A; Tripodi G; Rivabella L; Dozin B; Bruzzi P; Melioli G
Int J Immunopathol Pharmacol; 2011; 24(4):1005-16. PubMed ID: 22230406
[TBL] [Abstract][Full Text] [Related]
20. Expressions of CD8+TILs, PD-L1 and Foxp3+TILs in stage I NSCLC guiding adjuvant chemotherapy decisions.
Teng F; Meng X; Wang X; Yuan J; Liu S; Mu D; Zhu H; Kong L; Yu J
Oncotarget; 2016 Sep; 7(39):64318-64329. PubMed ID: 27602763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]